Sichenzia Ross Friedman Ference LLP Acted as Lead Investor Counsel on VBI Vaccines’ $5.25 million private placement
NEW YORK, August 1, 2014 (GLOBE NEWSWIRE) – New York – based securities law firm, Sichenzia Ross Friedman Ference LLP announces that it represented the lead investor in a $5.25 million private placement conducted by VBI Vaccines Inc. (NASDAQ: VBIV), formerly Paulson Capital (Delaware) Corp. The offering, which originally closed into escrow on July 25, 2013, consisted of the sale of one unit of VBI’s securities, made up of shares of Common Stock, Series A Preferred Stock and two class of warrants exercisable into shares of VBI’s Series B Preferred Stock. The release of the funds and securities in escrow was subject to certain conditions precedent which was satisfied on July 25, 2014, at which time the funds and securities were released.
VBI Vaccines, Inc. is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The Sichenzia Ross Friedman Ference LLP team was led by partner Harvey Kesner and associate Tara Guarneri-Ferrara.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Congratulates AYTU Biosciences, Inc., on NASDAQ Uplisting - October 19, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar and Fordham Financial Management in $6.75 Million Registered Direct Offering of Common Stock of Ampio Pharmaceuticals, Inc. - October 18, 2017
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017